EUVIMEDEUVIMED entdecken
Crossref

Hormonal Milieu–Dependent Cervicovaginal and Mammary Gland Effects of a Long-Acting Relaxin Agonist in Female Rats: A Nonclinical Evaluation Across Investigative Studies

Manoj Bhaskaran, Justin D. Vidal, Matthew M. Abernathy, John L. Vahle, Pragati S. Coder, Robert L. Johnson

Toxicologic Pathology · 19.11.2026

DOI: 10.1177/01926233261495558 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxicologic Pathology, online erschienen am 19.11.2026. Verfasst von Manoj Bhaskaran und 5 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical and vaginal epithelial hyperplasia and hyperkeratosis were observed in a 6-month repeat-dose toxicology study in rats administered the long-acting relaxin agonist (LY), with mammary fibroadenomas noted following a 6-month off-dose period. Two investigative studies characterized these findings: a 6-month study in intact and ovariectomized (OVX) rats with interim sacrifices at 1, 3, and 6 months, and a 12-month study in intact rats. In the 6-month study, no test article–related effects occurred in OVX rats, demonstrating dependence on an intact ovarian hormonal milieu. In intact rats, cervicovaginal hyperplasia/hyperkeratosis and stromal edema with or without cervical/vaginal prolapse progressed in incidence and severity as animals entered reproductive senescence, then plateaued with no progression to neoplasia. No effect on estrous cyclicity was observed. In the 12-month study, LY increased the incidence of mammary fibroadenomas and diffuse pituitary hyperplasia. These findings were attributed to an interaction between sustained relaxin pharmacology and age-related changes in endogenous hormones during progression through reproductive senescence. Rodent reproductive senescence differs fundamentally from human menopause, and this spectrum of hormonally dependent findings is likely rodent-specific but warrants consideration in clinical risk assessment in the context of human hormonal milieu and age.

Förderung

  • Eli Lilly and Company

Zitieren

APA

Bhaskaran, M., Vidal, J. D., Abernathy, M. M., Vahle, J. L., Coder, P. S., & Johnson, R. L. (2026). Hormonal Milieu–Dependent Cervicovaginal and Mammary Gland Effects of a Long-Acting Relaxin Agonist in Female Rats: A Nonclinical Evaluation Across Investigative Studies. Toxicologic Pathology. https://doi.org/10.1177/01926233261495558

Vancouver

Bhaskaran M, Vidal JD, Abernathy MM, Vahle JL, Coder PS, Johnson RL. Hormonal Milieu–Dependent Cervicovaginal and Mammary Gland Effects of a Long-Acting Relaxin Agonist in Female Rats: A Nonclinical Evaluation Across Investigative Studies. Toxicologic Pathology. 2026. doi:10.1177/01926233261495558

BibTeX
@article{Bhaskaran2026,
  author = {Bhaskaran, Manoj and Vidal, Justin D. and Abernathy, Matthew M. and Vahle, John L. and Coder, Pragati S. and Johnson, Robert L.},
  title = {Hormonal Milieu–Dependent Cervicovaginal and Mammary Gland Effects of a Long-Acting Relaxin Agonist in Female Rats: A Nonclinical Evaluation Across Investigative Studies},
  journal = {Toxicologic Pathology},
  year = {2026},
  doi = {10.1177/01926233261495558}
}
Kostenlos starten →